Working… Menu
Trial record 28 of 236 for:    PRASTERONE

Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00189124
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : May 18, 2016
Arthritis Foundation
Information provided by (Responsible Party):
Wendy Marder, University of Michigan

Brief Summary:

The purpose of this study is to evaluate the effect of DHEA on endothelial dysfunction in patients with systemic lupus by measuring:

  1. changes in brachial artery flow-mediated dilatation (FMD) and
  2. changes in biomarkers of cardiovascular risk. Patients will be enrolled in a randomized, double-blinded crossover trial of DHEA or placebo for ten weeks, then crossed over to the alternate treatment arm after a six-week washout period.

HYPOTHESIS: Dehydroepiandrosterone (DHEA) administration in premenopausal women with SLE modifies cardiovascular risk by improving vascular endothelial function and other biomarkers associated with cardiovascular heart disease.

Condition or disease Intervention/treatment Phase
Systemic Lupus Erythematosus Drug: Dehydroepiandrosterone (DHEA) Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus?
Study Start Date : September 2003
Actual Primary Completion Date : December 2005
Actual Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus
Drug Information available for: Prasterone

Primary Outcome Measures :
  1. Brachial artery reactivity, by flow mediated dilatation

Secondary Outcome Measures :
  1. Changes in biomarkers of SLE
  2. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female
  • Member of the Michigan Lupus Cohort
  • Meet the American College of Rheumatology (ACR) criteria for SLE
  • Premenopausal

Exclusion Criteria:

  • Smoker
  • Diabetic
  • Prednisone dose > 10 mg

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00189124

Layout table for location information
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan
Arthritis Foundation
Layout table for investigator information
Principal Investigator: Wendy Marder, MD University of Michigan

Layout table for additonal information
Responsible Party: Wendy Marder, Associate Professor, University of Michigan Identifier: NCT00189124     History of Changes
Other Study ID Numbers: 2001-0822
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: May 18, 2016
Last Verified: May 2016
Keywords provided by Wendy Marder, University of Michigan:
Systemic Lupus Erythematosus
Dehydroepiandrosterone (DHEA)
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs